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Summary 
Among the anti-neutrophil cytoplasmic antibodies (ANCA), those targeting proteinase 3 (PR3) 
have a high specificity for Wegener's granulomatosis (WG). It is known that a preceding prim- 
ing of neutrophils with cytokines is a prerequisite for membrane surface expression of PR3, 
which is then accessible  to autoantibody binding. Employing a monoclonal antibody directed 
against  human PR3 and ANCA-positive serum from WG patients with specificity for PR3, we 
now investigated the role of free arachidonic acid (AA) in autoantibody-related human neutro- 
phil  activation.  Priming  of neutrophils with  tumor necrosis  factor (TNF-or  for  15  rain  or 
exposure to anti-PR3 antibodies or incubation with free AA  (10  IxM) as sole events did not 
provoke superoxide generation, elastase secretion or generation of 5-1ipoxygenase products of 
AA. Similarly, the combination of TNF-oL-priming and AA incubation was ineffective. When 
TNF-cl-primed neutrophils were stimulated by anti-PR3  antibodies, superoxide and elastase 
secretion was provoked in the absence of lipid mediator generation. However, when free AA 
was additionally provided, a strong activation of the 5-1ipoxygenase  pathway was demasked, with 
the appearance of excessive quantities  ofleukotriene (LT)B4, LTA4, and 5-hydroxyeicosatetraenoic 
acid. Moreover, superoxide and elastase  secretion were markedly amplified, and studies with 
5-1ipoxygenase inhibitors and a LTB4-antagonist demonstrated this was due to an LTB4-related 
autocrine loop of celt activation. In contrast, the increased synthesis ofplatelet-activating factor 
in response to TNF-~x-priming and anti-PR3 stimulation did not contribute to the amplifica- 
tion loop of neutrophil activation under the given conditions. We conclude that anti-PR3 an- 
tibodies are potent inductors of the 5-1ipoxygenase pathway in primed human neutrophils, and 
extracellular free AA, as provided at an inflammatory focus, synergizes with the autoantibodies 
to evoke full-blown lipid mediator generation, granule secretion and respiratory burst.  Such 
events may be enrolled in the pathogenesis of focal necrotizing vascular injury in Wegener's 
granulomatosis. 
D 
espite its relatively low incidence, Wegener's granulo- 
matosis  (WG)  represents a major challenge for many 
disciplines in clinical medicine, chiefly because it is difficult 
to recognize and full-blown cases  have  a poor prognosis. 
Anti-neutrophil cytoplasmic antibodies  (ANCA),  directed 
against  granule  proteins  of polymorphonuclear  granulo- 
cytes (PMN) and monocytes, have been described in asso- 
ciation with WG and systemic vasculitis  (1, 2). At least two 
classes of  ANCA are distinguished by characteristic immuno- 
fluorescence  patterns:  the  cytoplasmic  (classic) c-ANCA 
and  the  perinuclear p-ANCA.  Proteinase  3  (PR3)  con- 
tained in azurophilic granules has been identified as the tar- 
get  antigen  of c-ANCA  staining  (3,  4),  while  p-ANCA 
staining is brought about by anti-myeloperoxidase antibod- 
ies  (5,  6);  the  identification  of additional  autoantigenic 
ANCA targets is under current research (7). 
The c-ANCA  fuorescence pattern has  a specificity for 
WG that is close to 95%, and the titer correlates well with 
disease  activity (8,  9),  thus suggesting that the related au- 
toantibodies are not only seromarkers of WG, but do pos- 
sess pathogenic significance. However, the mode in which 
c-ANCA stimulates PMN and evokes vascular injury is still 
elusive. It was shown that priming of neutrophils with cy- 
tokines,  as  occurring during  episodes  of infection or in- 
flammatory disease,  induces membrane surface expression 
of PR3,  which is then accessible  to autoantibody binding 
(10-13)  with  subsequent provocation of respiratory burst 
and PMN degranulation to a limited extent (6, 12, 14,  15). 
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and  a  monoclonal antibody manufactured against human 
PR3  (MoAB-P1K3),  we  now  asked  for  the  role  of free 
arachidonic acid (AA) in ANCA-related neutrophil activa- 
tion.  Our  interest in  this  precursor  of eicosanoids  stems 
from the fact that it is present in substantial quantities in the 
microenvironmental milieu of an inflammatory focus  (16, 
17),  and may activate PMN by cell-cell contact with en- 
dothelial cells (18-20); moreover it was previously noted to 
amplify inflammatory ligand-evoked neutrophil activation 
(21-23). We report here, that the presence ofAA demasks 
strong activation of the 5-1ipoxygenase pathway in autoanti- 
body-exposed human PMN, with generation of the potent 
chemoattractant leukotriene (LT)B  4 and, via triggering an 
autocrine loop of LTB4-related cell activation, provocation 
of full-blown PMN  mediator release.  These findings pro- 
vide new insights into the immunopathogenesis of the focal 
necrotizing vascular lesions characteristic for this enigmatic 
disease. 
Materials  and  Methods 
Preparation of Human PMN.  Within  a  group  of 30  healthy 
donors, 13 were noted to respond to ANCA-positive serum from 
WG  patients  in  pilot  experiments,  and  these  were  chosen  as 
blood donors. EDTA-anticoagulated blood was centrifuged in a 
Ficoll-Paque  (Pharmacia,  Uppsala,  Sweden)  gradient,  erythro- 
cytes were  sedimented  with polyvinyl alcohol (Merck-Schuchardt, 
Hohenbrunn, Germany) and residual erythrocytes  were removed 
by hypotonic lysis  as described previously (10). Cells were washed 
twice (150 g,  10 min, 4°C) and resuspended in phosphate-bufFered 
saline (298 mM) with Ca  >  and Mg  2+ (PBS) at a final concentra- 
tion of 5 X 10('/ml. Cell purity was >98% (Pappenheim staining) 
and cell viability >96% (trypan blue exclusion)  throughout. 
Analytical Procedu~vs.  LT  and  hydroxyeicosatetraenoic  acids 
(HETE)  were  analyzed  by HPLC  techniques as  previously de- 
scribed  (24, 25). These include extraction from cell supernatants 
by octadecylsilyl  solid  phase  extraction colunms, RP-HPLC  of 
methylated and non-methylated compounds and  SP-HPLC  of 
methylated compounds. LTA  4 was quantified by detection of its 
spontaneous degradation products (6-trans-diastereomeric  pair of 
LTB  4 and 5,6-DiHETEs), summed as LTA  4 decay. Platelet-acti- 
vating factor (PAY) release was determined by employing neutro- 
phils  prelabeled  with  l-O-[~H]alkyl-2-1yso-glycerophosphoryl  - 
choline with  subsequent SP-HPLC  analysis of labeled  PAY  as 
described before (26). Superoxide anion generation was measured 
as superoxide dismutase inhibitable cytochrome c reduction, and 
elastase according to standard procedures (26). 
Experimental Procedures.  For  priming, PMN  were  incubated 
with 0.5 ng/ml human recombinant TNF-o~ (Boehringer,  Mann- 
helm, Germany) for  15 rain. Stinmlation of the neutrophils was 
performed with 250 ng/ml MoAB-PP,3 (monoclonal antibody to 
human proteinase  3, designated WGM2 (11), 250 ng/ml F(ab)'  2- 
MoAB  (Fab fragment of the WGM2 monoclonal antibody; pu- 
rity was checked by SDS-Page  and was always higher than 95%) 
or 250 ng/ml nmrine control IgG1  (murine MoAB IgG, isotype 
control; Dranova, Hamburg, Germany), as well as 0.01,  0.1,  and 
1% vol/vol of IgG preparation three patients  with PPZ3-ANCA- 
positive established Wegener's granulomatosis.  Free AA was pro- 
vided at a concentration of 10 IxM AA, either as sole stmmlus, or 
at different time intervals after antibody/serum admixture, lnhib- 
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Figure 1.  Influence  of TNF priming, antibody stinmlation  and supply 
with free AA on neutrophil LTB  4 generation. 5 × 106 PMN were primed 
with TNF-o~ or sham-incubated for  15  lnin.  Next, anti-proteinase 3 
monoclonal  antibody (MoAB), its F(ab)'2  fragment, IgG1 or vehicle only 
(Control) was added. When indicated, free AA was additionally  admixed 
30 s later. Inhibitors and botulinum C2 toxin (C2) were co-applied with 
antibodies. IZeactions  were stopped after 15 min, and LTB  4  was  quanti- 
fied in the supernatant. Mean -+ SEM of five independent experiments 
each are given. Experiments with MoAB-PP,3, F(ab)'2MoAB-PP,3  and 
MoAB-PR3 + C2 sibmificantly  differed from control. 
itors, applied sinmltaneously  with the immunoglobulins  when in- 
dicated,  included the cyclooxygenase  inhibitor acetylsalicylic acid 
(ASA,  100  p.M; Bayer  AG, Leverkusen,  Germany), the  LTB  4- 
antagonist LY15779  (10 ~M, Eli Lilly & Company, Indianapolis, 
IN),  the  5-1ipoxygenase  inhibitor  nordihydroguaiaretic  acid 
(NDGA, 10 ~M; Sigma Chem. Co., St. Louis, MO), the 5-1ipoxy- 
genase inhibitor AA-886  (10  ~M;  Dr.  M.  Nishikawa,  Takeda 
Chemical Industries, Osaka, Japan)  and the  PAY-antagonist WEB 
2086  (10 bLM; Boehringer, Ingelheim, Germany). Botulinum C2 
toxin, which is composed of a membrane translocation compo- 
nent (C2,)  and a component (C21) effecting Al)P-ribosylation of 
non-muscle G-actin, thereby acting as a barbed end-capping pro- 
tein and effecting selective loss of the non-muscle F-actin content 
(30), was  graciously  provided  by  K.  Aktories  (Department  of 
Pharmacology,  University of Freiburg,  Freiburg,  Germany).  It 
was co-applied with antibodies at a concentration of 400 ng/ml 
C2~ and 800 ng/ml C2..  Reactions were stopped  by centrifuga- 
tion at 4°C for 5 rain at 1200,~. 
Statistics.  For statistical comparison, one-way analysis of vari- 
ance was performed. A level of P <(/.05 was considered as to be 
significant. 
Results 
TNF-o¢ priming of neutrophils per se  did not provoke 
any  significant lipid  mediator  generation,  superoxide  re- 
lease or elastase secretion (Figs.  1-4). This was also true for 
the  exposure  of non-primed PMN  to  MoAB-P1K3  and 
pooled ANCA-positive human serum. Incubation of TNF- 
primed  neutrophils  with  the  monoclonal antibody  pro- 
voked  the  liberation  of  some  very  minor  quantities  of 
LTB4,  5-HETE  and  LTA  a,  accompanied  by  superoxide 
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Figure 2.  Influence  of antibody  stimulation  and supply with free AA 
on neutrophil  5-HETE and LTA  4 release. 5  ￿  106 PMN were primed 
with TNF-c~ for 15 rain,  followed by the admixture  of anti-proteinase  3 
monoclonal antibody  (MoAB), lgG1 or vehicle only (Control). When in- 
dicated, fi-ee  AA was additionally admixed 30 s later. NDGA was co-applied 
with antibodies  when indicated.  Reactions were stopped  after  15  min, 
and the 5 lipoxygenase products were quantified in the supematant. Mean -+ 
SEM of five independent experiments  each are given. Experiments  with 
MoAB-PR3 significantly differed from control. 
Figure 3.  Influence of TNF priming,  antibody  stimulation  and supply 
with free AA on neutrophil  superoxide  generation.  5 ￿  106 PMN were 
primed with TNF-c~ or sham-incubated for 15 rain. Next, anti-proteinase 3 
monoclonal antibody  (MoAB), its F(ab)' 2 fragment, lgG1 or vehicle only 
(Control)  was added. When indicated,  free AA was additionally admixed 
30  s later.  Inhibitors  were co-applied  with antibodies.  Reactions were 
stopped  after  15  rain.  Mean  +  SEM  of five independent  experiments 
each are given.  Experiments  with MoAB-PR3, its F(ab)'2  fragment  and 
with MoAB-PR3 +  LY15779 significantly differed from control. 
generation and  elastase secretion.  In contrast,  control IgG1 
was totally ineffective. 
Exposure  of primed  PMN  to  free  AA did  not  enhance 
the  liberation  of leukotrienes,  superoxide  or  elastase  over 
baseline  levels.  However,  when  primed  neutrophils  were 
exposed to both MoAB-PR3  and free AA, a  dramatic  am- 
plification  of  5-1ipoxygenase  product  synthesis  ensued: 
LTB  4,  LTA  a and  5-HETE  were  all increased  to  >10-fold 
levels (10 ~M  AA) or even >25-fold levels (30  btM AA) as 
compared  to the various control groups.  This burst  of lipid 
mediator  release was  not reproduced  by  control  IgG1  and 
was  fully  suppressed  by  NDGA.  As  displayed  for  LTB4 
(Fig.  1), the F(ab)'2  fragment of MoAB-PR3  was approxi- 
mately  half as  effective as  the  complete  antibody,  and  co- 
exposure  of the cells to botulinum  C2  toxin and the LTB  4 
antagonist LY15779 did not affect the LT release. In the pres- 
ence of 1% homologous serum to provide complement fac- 
tors, the TNF  plus MoAB-PR3  plus AA-elicited 5-1ipoxy- 
genase product formation was not changed (data not given). 
Supply with  free AA also  markedly increased  the super- 
oxide  and  elastase  release  from  TNF-primed  PMN  in  re- 
sponse to MoAB-PR3,  which was not reproduced by con- 
trol IgG1.  Again,  the F(ab)'2  fragment  of MoAB-PR3  was 
approximately  half as  effective as  the  complete  antibody. 
5-1ipoxygenase  inhibition  with  NDGA  and  AA861  (used 
in  cases  of superoxide  detection,  since  NDGA  interferes 
with  this  assay),  and  the  presence  of the  LTB4-antagonist 
LY15779  suppressed  the  AA-related  increase  in  these  se- 
cretory responses.  ASA, in contrast,  was ineffective. 
The  enhancing  effect  of free  AA  on  MoAB-PR3-elic- 
ited  secretory  responses  in  TNF-primed  PMN  displayed 
distinct time dependency,  as shown  in  Fig.  5.  The highest 
efficacy was  noted for a lag time of 30 s between antibody 
admixture  and AA supply, which was therefore used in the 
routine protocol. 
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Figure 4.  Influence of TNF priming,  antibody  stmmlation  and supply 
with free AA on neutrophil elastase secretion. 5 ￿  106 PMN were primed 
with TNF-a or sham-incubated for 15 man. Next, anti-proteinase 3 mono- 
clonal antibody  (MoAB), its F(ab)'2 fragment, IgG1 or vehicle only (Con- 
trol) was added. When indicated,  free AA was additionally admixed  30 s 
later. Inhibitors were co-applied  with antibodies. Reactions were stopped 
after 15 min, and elastase was quantified in the supematant. Mean  +  SEM 
of five independent experiments each are given. Experiments with MoAB- 
PR3,  its  F(ab)' 2 fragnlent,  MoAB-PR3  +  ASA  and  MoAB-PR3  + 
LY15779 significantly differed from control. 
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Figure 5.  Influence of the lag time between antibody  stimulation  and 
AA supply on neutrophil  LTB  4 and elastase secretion. 5 X 10  ~' PMN were 
primed with TNF-u for 15 nfin. Next, anti-proteinase  3 monoclonal an- 
tibody  (MoAB) or IgG1 was added.  Free AA was co-applied  with anti- 
body or admixed  at different time intervals up to 60 s. Reactions were 
stopped after 15 rain, and the secretion products were analyzed in the su- 
pernatant.  Mean --- SEM of five independent  experiments each are given. 
Experiments with MoAB-PR3 significantly differed from control. 
Supply  with free AA also  markedly  enhanced  the secre- 
tory  responses  provoked  in  TNF-primed  neutrophils  by 
ANCA-positive  pooled  serum.  For  the  highest  titer  cur- 
rently used  (0.1%  serum,  vol/vol), the release of lipid me- 
diators  and  elastase  approached  60%  of  the  maximum 
secretory  responses  elicited  by  MoAB-PR3  under  these 
conditions. 
TNF-priming  of neutrophils  did not augment  the base- 
line  PAF  release  by  these  ceils.  Subsequent  exposure  to 
MoAB-PR3  enhanced  the liberation of this lipid mediator 
to  35  +  5  ng/5  ￿  106  PMN  (10  min  incubation  time), 
whereas  control  IgG1  was  ineffective  (3.4  +-  1.3  ng/5  ￿ 
106  PMN).  Co-supply  with  free  AA did  not  further  aug- 
ment  the  MoAb-PR3-related  PAF  release.  The  provoca- 
tion of LT generation as well as superoxide and elastase re- 
lease  by  TNF  plus  MoAB-PR3  plus  AA  were  not 
suppressed  in  the  presence  of the  PAF  antagonist  WEB 
2086  (data not shown). 
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Figure  6.  Postulated  sequence  of ANCA-induced PMN  activation- 
role  of cytokine  priming and  exogenous  free AA supply.  (I)  Quiescent 
PMN without PR3-membrane expression.  (2) Cytokine-induced mem- 
brane expression of PR3. (3) ANCA-binding to PR3 target antigen with 
possible antigen-Fc-receptor bridging.  (4) Activation  of intercellular leu- 
kotriene synthesis in the presence of free AA (liberated from inflaminatory 
tissue). LTB4-mediated  autocrine  amplification  of inflammatory  PMN- 
responses. Shift of the PMN-derived leukotriene  intermediate  LTA4 to 
adjacent  endothelial  cells with transcellular synthesis of vasoactive  cys- 
teinyl LTs (LTC  4, LTD  4, LTE4). 
Discussion 
It has previously been shown that  the priming of human 
neutrophils with cytokines such  as TNF-a  induces a trans- 
location of PR3  from the intragranular  loci to the cell sur- 
face  (10-13),  notwithstanding  the  question  whether  this 
proceeds  only via membrane  fusion  or requires  additional 
receptor  binding  of PR3  on  the  neutrophil  plasma  mem- 
brane.  Binding  of the  autoantibodies  to  these  targets  then 
evidently  triggers  cell  signaling  events,  and  the  presently 
Table  1.  Neutrophil Stimulation by ANCA-positive Pooled Human Serum-impact of Free AA* 
ANCA-Serum  LTB4  LTA4  5-HETE  Elastase 
pmol/5*  106 PMN  pmol/5*  106 PMN  pmol/5*  106 PMN  % of total 
0.01%  +AA  12.37  +  0.79  7.71  _+ 0.76  23.87  +  1.9l  16.37  +  1.49 
-AA  1.13  +  0.09  0.83  _+ 0.06  1.37  _+ 0.29  5.73  _+ {).57 
0.1%  +AA  18.45  •  0.37  10.95  +  1.29  32.43  _+ 2.45  23.58  -- 0.29 
-AA  1.43  •  0.09  0.93  +  0.06  1.57  •  0.09  9.03  +  {).96 
*5 ￿  I{P PMN were primed with TNF-cx for 15 rain,  different concentrations of ANCA-positive pooled hmnan serum were admixed, and free AA 
was additionally  added  30 s later when indicated.  Metabolite release after  15 rain  reaction time is given (mean  +- SEM of five independent experi- 
ments each). 
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previous studies in this field (6,  12,  14,  15).  There is con- 
troversy whether  the  signaling  is  directly related  to  the 
binding of the F(ab)'  domain,  or additionally or even ex- 
clusively proceeds  via  antibody  binding  to  co-expressed 
Fc-receptors (14,  15, 28, 29); the present data with F(ab)' 2 
fragments  support  the  view  that  both  antibody  domains 
may be involved. The subsequent signal transduction path- 
way is largely unsettled; phenomena of antibody and recep- 
tor internalization are apparently not enrolled, as disrupture 
of the  neutrophil  F-actin  content  with  botulinum  C2- 
toxin (30) did not suppress the PMN mediator generation. 
The current findings do, however, strongly support the no- 
tion that activation of the PMN 5-1ipoxygenase pathway is 
an important feature in the cascade of events. As similarly 
noted for neutrophil stimulation  by inflammatory ligands 
(21-23), this may occur without major stimulation of neu- 
trophil phospholipases, thus explaining the very low quan- 
tities of Lts and HETEs in cytokine plus antibody-exposed 
PMN in the absence of exogenous AA. Extracellular supply 
with this fatty acid may then compensate for the restricted 
availability of endogenous precursor to be readily metabo- 
lized to 5-1ipoxygenase products. The finding of an optimal 
interval between  antibody admixture  and  exogenous AA 
supply of--30  s may be  explained by the  fact that  even 
quiescent neutrophils display rapid uptake of exogenously 
offered free fatty acids  (31, 32) with subsequent incorpora- 
tion  into  different phospholipid  species,  which  results  in 
rapidly decreasing precursor availability for the  5-1ipoxy- 
genase pathway if the exogenous AA is offered "too early" 
(33, 34). 
The total amounts of 5-1ipoxygenase products elicited by 
the monoclonal antibodies to PP,3 and the ANCA-positive 
serum in the presence of free AA approached the quantities 
elicited by the calcium ionophore A23187, the most potent 
stimulus  for PMN  lipoxygenase metabolism  hitherto  de- 
scribed  (22,  23).  LTB  4  and  5-HETE  are  well-known 
chemoattractants,  capable  of recruiting additional  neutro- 
phils  to  an  inflammatory focus  (35).  The  PMN-derived 
LTA  4 has been shown to be shifted to adjacent endothelial 
cells,  with  transcellular synthesis of the  pro-inflammatory 
cysteinyl Lts by use of the enzymatic equipment of this ac- 
ceptor cell type (18, 24, 36, 37). Moreover, the present data 
demonstrate that the arising LTB  4 serves as potent autocrine 
amplification  loop  for  full-blown  activation  of autoanti- 
body-exposed neutrophils: both the superoxide release and 
the elastase secretion were markedly increased in the pres- 
ence of AA,  and this increase was completely blocked by 
different 5-1ipoxygenase inhibitors and a specific LTB  4 re- 
ceptor antagonist.  Such an  autocrine function of LTB  4 is 
well in line with the previously characterized efficacy pro- 
file of this autacoid in human neutrophils (35).  In contrast, 
the  second autoantibody-evoked autacoid,  PAF,  did  evi- 
dently not substantially contribute to the autocrine loop of 
neutrophil activation under the present experimental con- 
ditions, as deduced from the inefficacy of the PAF antago- 
nist WEB 2086. We did not address the question, whether 
some suppression of PAF-binding to ANCA-exposed neu- 
trophils,  as previously suggested (29),  might contribute to 
this finding. 
We conclude that,  in addition to their direct prosecre- 
tory effect in PMN, anti-PR3 antibodies are potent induc- 
tors of human neutrophil 5-1ipoxygenase metabolism, with 
the  arising  LTB  4 serving as  autocrine  amplification loop. 
These observations suggest a "three hit" scenario: when the 
presence of autoantibodies is supplemented with cytokine 
priming of circulating neutrophils and the presence of free 
AA at an inflammatory focus, a vicious cycle of focal accu- 
mulation of neutrophils, full-blown activation of these cells 
and  further  PMN  recruitment  may  ensue,  which  could 
then cause the severe necrotizing vascular injury known to 
be the hallmark of WG. The current findings thus further 
support and substantially extend the concept that c-ANCAs 
represent not only the best seromarker for WG so far avail- 
able,  but  are  centrally involved  in  the  pathogenetic  se- 
quelae of this disease. 
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